---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-025075"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:26:35.480888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027

## Summary
- Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.
- ABS-201 NHP data show extended half-life and >90% subcutaneous bioavailability; Phase 1 start targeted early 2026.
- Q1 2025 revenue $1.2M (up from $0.9M YoY); net loss $26.3M vs $22.0M; R&D spending rose to $16.4M.
- Cash, equivalents, and short-term investments of $134.0M sufficient to fund operations into first half of 2027.
- Company expects to sign one or more new partnerships, including with a large pharma, in 2025.

## SEC filing metadata
- accession: 0001628280-25-025075
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/0001628280-25-025075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/absc-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-025075
- JSON: https://secwatch.observer/filing/0001628280-25-025075.json
- Plain text: https://secwatch.observer/filing/0001628280-25-025075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.